|

pIFN (peginterferon alfa-2a) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Diakonos Oncology Corporation1

Indications

  • Refractory Melanoma1
  • Cancer1

Birmingham, Alabama1 trial

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

The University of Alabama

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.